Although there is a paucity of molecular epidemiological data to validate hypotheses, it has been noted that a structural variant of PER3 was associated with the incidence of breast cancer in young women [82] and those that have PER3 variants also have a higher burden of long-term toxicity of treatment. This evidence concerns the gene PER3 and breast cancer.